You are here: Home » Economy & Policy » News
Govt's edible oil duty cut to have little impact on prices, say traders
Indian scientists working on developing mRNA vaccine technology get grant
Business Standard

NPPA allows 50% price hike for ibuprofen, ranitidine, carbamazepine

These are scheduled drugs (or ones that are under price control) and low priced

Topics
NPPA | Pharma industry | drugs

Sohini Das  |  Mumbai 



drugs, pharma, prices, drug prices, medicines, health
Some of the companies that stand to benefit by the move are Torrent Pharmaceuticals, Cadila Pharmaceuticals, Zydus Cadila, and J B Chemicals as they have top-selling ranitidine brands | Illustration: Binay Sinha

India’s pharmaceutical pricing regulator has allowed a one-time price hike of 50 per cent for three key -- ibuprofen (analgesic), ranitidine (antacid), and carbamazepine (epilepsy) -- that are used as the first line of treatment.

TO READ THE FULL STORY, SUBSCRIBE NOW NOW AT JUST RS 249 A MONTH.

SUBSCRIBE TO INSIGHTS

What you get on Business Standard Premium?

  • icon Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • icon Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • icon Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
  • icon Pick your 5 favourite companies, get a daily email with all news updates on them.
  • icon 26 years of website archives.
  • icon Preferential invites to Business Standard events.

OR


Subscribe to Business Standard Premium

Exclusive Stories, Curated Newsletters, 26 years of Archives, E-paper, and more!

Insightful news, sharp views, newsletters, e-paper, and more! Unlock incisive commentary only on Business Standard.

Download the Business Standard App for latest Business News and Market News .

First Published: Sat, July 03 2021. 02:18 IST

RECOMMENDED FOR YOU

.